腔静脉滤器置入及「预防性」使用的趋势
基于美国全国住院患者样本2000至2014年的回顾性观察研究显示,成人住院患者腔静脉滤器置入率初期快速上升,2005年PREPIC2试验发表后增速放缓,2010年FDA安全警示后开始下降;预防性置入占比在FDA警示后下降并稳定在18.5%。
要点
- 腔静脉滤器总置入率初期快速上升(APC 11.2%),PREPIC2试验发表后增速放缓(APC 4.4%),FDA安全警示后转为下降(APC -5.5%)。
- 预防性腔静脉滤器置入占比在PREPIC2发表后增速放缓,FDA警示后下降,最后3年稳定在18.5%。
- 手术创伤(OR 10.9)、骨科手术(OR 4.7)和神经外科手术(OR 3.9)与预防性腔静脉滤器置入关联最强。
核心结论
- PREPIC2试验发表使预防性腔静脉滤器置入增长放缓,而FDA安全警示影响更大,导致预防性腔静脉滤器使用率下降。
- 作者认为需进一步研究创伤、骨科和神经外科患者的预防性腔静脉滤器置入,以确定当前使用水平是否合理。
研究设计与样本
- 利用全国住院患者样本(National Inpatient Sample)对美国2000至2014年成人住院患者进行的回顾性观察研究。
- 共纳入461,904,314例成人住院患者,中位年龄58.1岁(四分位距38.5-74.3岁),男性占39.6%。
主要发现
- 腔静脉滤器置入率从0.19%升至0.35%(APC 11.2%,95%CI 10.3%-12.2%,P<.001),PREPIC2试验发表后从0.35%升至0.42%(APC 4.4%,95%CI 2.8%-6.0%,P<.001),FDA安全警示后从0.42%降至0.32%(APC -5.5%,95%CI -6.5%至-4.6%,P<.001)。
- 预防性腔静脉滤器占总置入的百分比在PREPIC2试验发表前快速上升(APC 19.5%,95%CI 17.9%-21.0%,P<.001),发表后增速放缓(APC 4.4%,95%CI 2.6%-6.2%,P<.001),FDA安全警示后下降,最后3年稳定在18.5%(APC -0.3%,95%CI -2.2%至1.7%,P=.8)。
- 与预防性腔静脉滤器置入关联最强的亚组为手术创伤(OR 10.9,95%CI 10.2-11.7)、骨科手术(OR 4.7,95%CI 4.3-5.2)和神经外科手术(OR 3.9,95%CI 3.6-4.2)。
- 除骨科手术外,所有组在PREPIC2试验发表后预防性腔静脉滤器增长均减速;除其他大型手术外,所有组在FDA安全警示后预防性腔静脉滤器置入均减少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需进一步研究创伤、骨科和神经外科患者的预防性腔静脉滤器置入,以确定当前使用水平是否合理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prophylactic vena cava filter (VCF) use in patients without venous thromboembolism is common practice despite ongoing controversy. Thorough analysis of the evolution of this practice is lacking. We describe trends in VCF use and identify events associated with changes in practice. METHODS: Using the National Inpatient Sample, we conducted a retrospective observational study of U.S. adult hospitalizations from 2000 to 2014. Trends in prophylactic VCF insertion were analyzed both across the entire study population and within subgroups according to trauma status and type of concurrent surgery. Annual percentage change (APC) was calculated, and trends were analyzed using Poisson regression. RESULTS: Among 461,904,314 adult inpatients (median [interquartile range] age, 58.1 [38.5-74.3] years; 39.6% male), the incidence of VCF insertion increased rapidly at first (from 0.19% to 0.35%; APC, 11.2%; 95% confidence interval [CI], 10.3%-12.2%; P < .001), then at a slower rate after the publication of the Prévention du Risque d'Embolie Pulmonaire par Interruption Cave 2 (PREPIC2) trial in 2005 (from 0.35% to 0.42%; APC, 4.4%; 95% CI, 2.8%-6.0%; P < .001), and it began decreasing after the 2010 Food and Drug Administration (FDA) safety alert (from 0.42% to 0.32%; APC, -5.5%; 95% CI, -6.5% to -4.6%; P < .001). The percentage of total VCFs that had a prophylactic indication increased quickly before publication of the PREPIC2 trial (APC, 19.5%; 95% CI, 17.9%-21.0%; P < .001), increased at a slower rate after publication in 2005 (APC, 4.4%; 95% CI, 2.6%-6.2%; P < .001), and dropped after the FDA safety alert, stabilizing at 18.5% for the last 3 years (APC, -0.3%; 95% CI, -2.2% to 1.7%; P = .8). Subgroups most associated with prophylactic VCF insertion were operative trauma (odds ratio [OR], 10.9; 95% CI, 10.2-11.7), orthopedic surgery (OR, 4.7; 95% CI, 4.3-5.2), and neurosurgical procedures (OR, 3.9; 95% CI, 3.6-4.2). All groups except orthopedic surgery experienced a deceleration in prophylactic VCF growth after the publication of PREPIC2. Meanwhile, the FDA safety alert was associated with a decrease in prophylactic VCF insertions for all groups except other major surgery. CONCLUSIONS: Whereas publication of the PREPIC2 trial led to a deceleration in prophylactic VCF insertion growth, the FDA alert had a bigger impact, leading to declining rates of prophylactic VCF use. Further investigations of prophylactic insertion of VCF in trauma, orthopedic, and neurosurgical patients are needed to determine whether current levels of use are justified.
引用
- Power JR, Nakazawa KR, Vouyouka AG, et al. Trends in vena cava filter insertions and "prophylactic" use. J Vasc Surg Venous Lymphat Disord. 2018. PMID: 29678686. doi:10.1016/j.jvsv.2018.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。